Mycophenolate mofetil as maintenance therapy in patients with vasculitis and renal involvement

Clinical Nephrology

Volumn 72, Issue 1, 2009, Pages 31-37

  Iatrou, C ^a,c   Zerbala, S ^a   Revela, I ^a   Spanou, E ^a   Marinaki, S ^b   Nakapoulou, L ^b   Boletis, J ^b  

^a General Hospital of Nikea   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c NONE   (Greece)

Author keywords

ANCA; Mycophenolate mofetil; Vasculitis

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; NEUTROPHIL CYTOPLASMIC ANTIBODY;

AMYLASE BLOOD LEVEL; ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; ARTICLE; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATURIA; HEMODIALYSIS; HERPES ZOSTER; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; PROTEINURIA; RECURRENCE RISK; REMISSION; SIDE EFFECT; URINE SEDIMENT; WEGENER GRANULOMATOSIS; CHI SQUARE DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; KIDNEY DISEASE; KIDNEY FUNCTION TEST; NONPARAMETRIC TEST; TREATMENT OUTCOME; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHI-SQUARE DISTRIBUTION; CYCLOPHOSPHAMIDE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MYCOPHENOLIC ACID; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VASCULITIS;

EID: 70349245534     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp72031     Document Type: Article

References (28)

1. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant. 1996; 10: 77-84.
2. Booth AD, Pusey CD, Jayne DR. Renal vasculitis: an update in 2004. Nephrol Dial Transplant. 2004; 19: 1964-1968.
3. Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis. 2007; 50: 248-256.
4. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Carruthers DM, Moots R. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol. 1998; 37: 57-63.
5. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005; 353: 2219-2228.
6. Guillevin L, Cordier JF, Lhote F et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997; 40: 2187-2198.
7. Haroun MK, Stone JH, Nair R, Racusen L, Hellmann DB, Eustace JA. Correlation of percentage of normal glomeruli with renal outcome in Wegener's granulomatosis. Am J Nephrol. 2002; 22: 497-503.
8. Haubitz M, Schellong S, Göbel U et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998; 41: 1835-1844.
9. Hauer HA, Bajema IM, Van Houwelingen HC et al. Determinants of outcome in ANCA-associated glomerulonephritis: A prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002; 62: 1732-1742.
10. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener's Granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-498.
11. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate Mofetil Versus Cyclophosphamide for Inducing Remission of ANCAVasculitis with Moderate Renal Involvement. Nephrol Dial Transplant. 2008; 23: 1307-1312.
12. Ibernon M, Poveda R, Vidaller A, Bestard O, Grinyó JM. Mycophenolate mofetil in anti MPO renal vasculitis: an alternative therapy in case of cyclophosphamide or azathioprine toxicity.Clin Nephrol 2008; 69: 395-401.
13. Jayne D, Rasmussen N, Andrassy K et al. Arandomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003; 349: 36-44.
14. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994; 37: 187-192.
15. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant. 2005; 20: 2725-2732.
16. Kapitsinou PP, Ioannidis JP, Boletis JN et al. Clinicopathologic predictors of death and ESRD in patients with pauci-immune necrotizing glomerulonephritis. Am J Kidney Dis. 2003; 41: 29-37.
17. Koldingsnes W, Gran JT, Omdal R, Husby G. Wegener's granulomatosis: long-term follow-up of patients treated with pulse cyclophosphamide. Br J Rheumatol. 1998; 37: 659-664.
18. Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract. 2006; 102: 100-107.
19. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment ofWegener's Granulomatosis. Arthritis Rheum. 2004; 51: 278-283.
20. Luqmani R, Exley A, Kitas G, Bacon P. Disease assessement and management of the vasculitides. Bailliere's Clin Rheumatol 1997; 11: 423-446.
21. Neumann I, Kain R, Regele H, Soleiman A, Kandutsch S, Meisl FT. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol Dial Transplant. 2005; 20: 96-104.
22. Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol. 1999; 10: 1965-1971.
23. Rihová Z, Jancová E, Merta M et al. Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA-associated vasculitis - preliminary single center experience. Prague Med Rep. 2004; 105: 64-68.
24. Reinhold-Keller E, Kekow J, Schnabel A et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum. 1994; 37: 919-924.
25. Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis. 2007; 66: 798-802.
26. Zhu B, Chen N, Lin Y et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007; 22: 1933-1942.
27. Waiser J, Budde K, Braasch E, Neumayer HH. Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil. Am J Kidney Dis. 1999; 34: e9.
28. Westman KW, Bygren PG, Ericsson UB, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. Am J Nephrol. 1998; 18: 274-279.